Publication: Identificación y caracterización del componente proteico de la especialidad farmacéutica Inmunoferon®
Loading...
Files
Official URL
Full text at PDC
Publication Date
2016-06-30
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El sistema inmune es el sistema de defensa del organismo involucrado en la protección frente a microorganismos patógenos y neoplasias. Este sistema está formado por una gran variedad de células y moléculas capacitadas para reconocer específicamente estructuras moleculares o antígenos y desarrollar una respuesta inmune que conduce a su eliminación. Sin embargo, en ocasiones esta respuesta puede estar alterada provocando enfermedades derivadas de respuesta insuficiente (inmunodeficiencias, infección, neoplasias), o de respuesta excesiva (alergia, autoinmunidad, rechazo de trasplantes). La estrategia terapéutica utilizada para restaurar el correcto funcionamiento de la respuesta inmune, estimulándola o suprimiéndola, se conoce como inmunomodulación. Para lograr la inmunomodulación se utilizan agentes inmunomoduladores de naturaleza muy variada que incluyen sustancias sintéticas, recombinantes y de origen natural. Dentro de este último grupo cabe destacar a los inmunomoduladores diseñados con el objetivo de estimular mecanismos de inmunidad natural. A este grupo pertenece el fármaco español Inmunoferon®. Se trata de un inmunomodulador oral que ha demostrado capacidad para normalizar la función efectora de las células accesorias y fagocíticas, de las células NK y de los linfocitos T. Simultáneamente, inhibe la producción de TNF-α y modula la producción de otras citoquinas reguladoras (IL-1, IL-2, IL-12, IFN- γ). Se ha empleado en enfermedades diversas, como la hepatitis B crónica, la enfermedad pulmonar obstructiva crónica, la estomatitis aftosa y la inflamación muscular, entre otras. El principio activo de la especialidad Inmunoferon® es una asociación no covalente de polisacárido/proteína absorbida sobre una matriz estabilizante de sulfato y fosfato cálcicos. El polisacárido es un glucomanano de la pared de Candida utilis y el componente proteico procede de semillas no germinadas de ricino (Ricinus communis). Hasta el presente, el desconocimiento total de la naturaleza de este componente proteico ha impedido estudiar y conocer en profundidad la compleja farmacología de este fármaco...
The immune system is the body's defence system involved in protection against micro-organisms, pathogens and neoplasia. This system is comprised of a large variety of cells and molecules able to specifically recognise molecular structures or antigens and carry out an immune response that leads to their removal. However, at times this response may be altered leading to diseases arising from insufficient response (immunodeficiency, infection, and neoplasia) or excessive response (allergy, autoimmunity, transplant rejection). The therapeutic strategy used to restore correct operation of the immune response, either by stimulating or suppressing it, is known as immunomodulation. Highly varied immunomodulator agents are used to attain immunomodulation; these include synthetic, recombinant and natural origin substances. Within the latter group immunomodulators designed with the aim of stimulating natural immunity mechanisms are notable. The Spanish drug Inmunoferon® belongs to this group. This is an oral immunomodulator which has proved its ability to normalise the effector function of accessory and phagocytic cells, natural killer cells and T lymphocytes. At the same time it inhibits the production of TNF-α and modulates the production of other regulatory cytokines (IL-1, IL-2, IL-12, IFN- γ ). It has been used in various diseases such as chronic hepatitis B, chronic obstructive pulmonary disease, apthous stomatitis and muscular inflammation, among others. The active substance of the specialty Inmunoferon® is a non-covalent association of polysaccharide/protein absorbed on a stabilising matrix of calcium sulphate and phosphate. The polysaccharide is a glucomannan from the Candida utilis wall and the protein component arises from non-germinated ricin seeds (Ricinus communis). To date, the total lack of knowledge over the nature of this protein component has hindered studying and ascertaining in depth the complex pharmacology of this drug...
The immune system is the body's defence system involved in protection against micro-organisms, pathogens and neoplasia. This system is comprised of a large variety of cells and molecules able to specifically recognise molecular structures or antigens and carry out an immune response that leads to their removal. However, at times this response may be altered leading to diseases arising from insufficient response (immunodeficiency, infection, and neoplasia) or excessive response (allergy, autoimmunity, transplant rejection). The therapeutic strategy used to restore correct operation of the immune response, either by stimulating or suppressing it, is known as immunomodulation. Highly varied immunomodulator agents are used to attain immunomodulation; these include synthetic, recombinant and natural origin substances. Within the latter group immunomodulators designed with the aim of stimulating natural immunity mechanisms are notable. The Spanish drug Inmunoferon® belongs to this group. This is an oral immunomodulator which has proved its ability to normalise the effector function of accessory and phagocytic cells, natural killer cells and T lymphocytes. At the same time it inhibits the production of TNF-α and modulates the production of other regulatory cytokines (IL-1, IL-2, IL-12, IFN- γ ). It has been used in various diseases such as chronic hepatitis B, chronic obstructive pulmonary disease, apthous stomatitis and muscular inflammation, among others. The active substance of the specialty Inmunoferon® is a non-covalent association of polysaccharide/protein absorbed on a stabilising matrix of calcium sulphate and phosphate. The polysaccharide is a glucomannan from the Candida utilis wall and the protein component arises from non-germinated ricin seeds (Ricinus communis). To date, the total lack of knowledge over the nature of this protein component has hindered studying and ascertaining in depth the complex pharmacology of this drug...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Ciencias Biológicas, Departamento de Bioquímica y Biología Molecular I, leída el 05/02/2016